AXIN2 Polymorphisms, the β-Catenin Destruction Complex Expression Profile and Breast Cancer Susceptibility

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The Wnt/β-catenin signaling pathway regulates crucial cellular functions, including proliferation and survival.
• Aberrant Wnt/β-catenin signaling is implicated in tumor initiation and progression, particularly in breast cancer.
• Mutations in β-catenin account for only 30% of aberrant signaling in breast cancer, suggesting other pathway components are involved.

Purpose of the Study:

• To investigate the association of AXIN2 polymorphisms (rs2240308 and rs151279728) with breast cancer risk.
• To analyze the expression profiles of β-catenin destruction complex genes in breast cancer patients.

Main Methods:

• Peripheral blood samples were collected from 102 breast cancer patients and 102 healthy controls.
• Genotyping of AXIN2 polymorphisms was performed using PCR-RFLPs and DNA sequencing.
• Gene expression levels were quantified using quantitative real-time PCR (RT-qPCR).

Main Results:

• Significant associations were found between AXIN2 rs151279728 and rs2240308 polymorphisms and breast cancer risk.
• AXIN2 gene expression levels were significantly elevated in breast cancer patients compared to controls.
• Expression of APC, β-catenin, CK1α, GSK3β, and PP2A genes correlated with clinic-pathological characteristics.

Conclusions:

• This study provides the first evidence that AXIN2 genetic defects and altered expression of the β-catenin destruction complex are present in breast cancer patients.
• These findings support the role of Wnt/β-catenin pathway dysfunction in breast cancer tumorigenesis.
• Further research is needed to determine the functional implications of these genetic alterations.